Thursday, January 03, 2019 8:55:01 AM
https://globenewswire.com/news-release/2019/01/03/1680152/0/en/Captor-Capital-CEO-takes-Common-Shares-in-lieu-of-Cash-Salary-and-Bonuses.html
TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Captor Capital Corp. (“Captor” or the “Company”) (CSE: CPTR; FRANKFURT: NMV; STUTTGART: NMVA; USOTC: NWURF), a cannabis-focused investment company, announced today that CEO of Captor, John Zorbas, was issued 233,333 common shares at a deemed issue price of $1.50 in lieu of receiving $350,000 in deferred and unpaid salary and bonuses owing to Mr. Zorbas. Mr. Zorbas said “Captor has valuable and promising cannabis assets and I believe strongly in the long-term success of Captor’s business. Converting my unpaid salary into shares, further aligns my interests with the interests of our shareholders.”
About Captor Capital
Captor Capital Corp. is a Canadian firm focused on the cannabis sector listed on the Canadian Securities Exchange, the OTC, and the Frankfurt and Stuttgart stock exchanges. A vertically integrated cannabis company, Captor provides recreational and medical marijuana based products to consumers via its leading brands and dispensary locations. Listed on the Canadian Securities Exchange, the OTCUSA, and the Frankfurt Stock Exchange, Captor owns and operates advanced growing facilities which produce consistent high quality contaminant free marijuana for its customers, as well as other high demand cannabis based goods for consumption. The Company follows a strategy of acquiring cash flowing established companies and organizations with growth potential that require capital to scale. Captor currently has a number of revenue generating cannabis investments including the world famous West Hollywood MedMen branded dispensary, CHAI in Santa Cruz and Higher Level, Castroville. The Company also owns Mellow Extracts, a highly regarded producer of cannabis extracts based in Costa Mesa, CA. Captor Capital is currently looking at additional revenue generating investments in the cannabis space and will be updating the market in due course.
Contact
Gavin Davidson, Communications
Captor Capital Corp.
647.524.5479
gavin@captorcapital.com
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM